Yipinhong Pharmaceutical Co Ltd Class A Asset Resilience Ratio
Yipinhong Pharmaceutical Co Ltd Class A asset resilience ratio. Yipinhong Pharmaceutical Co Ltd Class A (300723) has an Asset Resilience Ratio of 1.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300723 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Yipinhong Pharmaceutical Co Ltd Class A (2019–2024)
Asset resilience ratio of Yipinhong Pharmaceutical Co Ltd Class A from 2019 to 2024. This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. Read Yipinhong Pharmaceutical Co Ltd Class A total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300723 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥45.33 Million | 1.01% |
| Total Liquid Assets | CN¥45.33 Million | 1.01% |
Asset Resilience Insights
- Limited Liquidity: Yipinhong Pharmaceutical Co Ltd Class A maintains only 1.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yipinhong Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Yipinhong Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Yipinhong Pharmaceutical Co Ltd Class A Asset Resilience Ratio by Year (2019–2024)
Yipinhong Pharmaceutical Co Ltd Class A asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Yipinhong Pharmaceutical Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | CN¥4.75 Million ≈ $694.52K |
CN¥4.40 Billion ≈ $644.46 Million |
-0.81pp |
| 2023-12-31 | 0.92% | CN¥40.44 Million ≈ $5.92 Million |
CN¥4.41 Billion ≈ $644.63 Million |
-0.84pp |
| 2022-12-31 | 1.76% | CN¥72.19 Million ≈ $10.56 Million |
CN¥4.10 Billion ≈ $599.73 Million |
+1.36pp |
| 2021-12-31 | 0.41% | CN¥15.03 Million ≈ $2.20 Million |
CN¥3.70 Billion ≈ $542.07 Million |
-0.20pp |
| 2020-12-31 | 0.61% | CN¥13.00 Million ≈ $1.90 Million |
CN¥2.15 Billion ≈ $313.90 Million |
-1.38pp |
| 2019-12-31 | 1.98% | CN¥35.60 Million ≈ $5.21 Million |
CN¥1.79 Billion ≈ $262.64 Million |
-- |
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more